Alzamend Neuro Inc. Common Stock (ALZN)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I look for durable businesses with earnings, cash, and a moat. Alzamend Neuro fails most of those tests. It is a $6.5M market-cap biotech with just four employees, developing AL001 and ALZN002 for neurodegenerative and psychiatric disorders. No revenue appears in any filed period. Losses are persistent: in fiscal 2024, ended 2024-04-30, net loss was $9.9M; in fiscal 2025, ended 2025-04-30, net loss was $4.5M; in fiscal 2026, ended 2026-04-30, net loss was $8.8M. In fiscal Q1 2027, ended 2026-07-31, the company lost another $3.0M. FairStock's trailing free cash flow is -$6.8M, a -105% FCF yield against that $6.5M market cap, so the business consumes cash far faster than its equity value. The balance-sheet and quality scores are ugly: Piotroski 1/9, Altman Z -9.33, ROE -163.23%, ROCE -76.44%. At the 2026-10-13 close of $1.35, P/E is -0.59 and P/B is 1.13; with no earnings or revenue, I cannot call it cheap on Graham grounds. The moat is nonexistent until clinical data or approvals exist, and the Peter Lynch category is none because of four straight loss years. Growth is only a hope: any value depends on trials, regulatory outcomes, and financing. Until cash flow turns or a partner validates the science, this is speculation, not investment.

In plain English: Alzamend Neuro is a tiny early-stage drug company with only four employees. It is trying to develop treatments for Alzheimer's, bipolar disorder, and other brain-related conditions, but it has no product sales and has lost money every year shown. At $1.35, the stock looks speculative rather than cheap because there are no profits or revenue to support the price.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-07-31) · fiscal Q3 2026 10-Q (period ended 2026-01-31) · fiscal Q2 2026 10-Q (period ended 2025-10-31) · fiscal Q1 2026 10-Q (period ended 2025-07-31) · FY2026 10-K (period ended 2026-04-30) · FY2025 10-K (period ended 2025-04-30) · FY2024 10-K (period ended 2024-04-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer